21. Safety, pharmacokinetics and pharmacodynamics of BI 135585, a selective 11β‐hydroxysteroid dehydrogenase‐1 (HSD1) inhibitor in humans: liver and adipose tissue 11β‐HSD1 inhibition after acute and multiple administrations over 2 weeks. Issue 5 (10th March 2016) Authors: Freude, S.; Heise, T.; Woerle, H.‐J.; Jungnik, A.; Rauch, T.; Hamilton, B.; Schölch, C.; Huang, F.; Graefe‐Mody, U. Journal: Diabetes, obesity & metabolism Issue: Volume 18:Issue 5(2016) Page Start: 483 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
22. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes. Issue 7 (17th February 2013) Authors: Heise, T.; Seewaldt‐Becker, E.; Macha, S.; Hantel, S.; Pinnetti, S.; Seman, L.; Woerle, H. J. Journal: Diabetes, obesity & metabolism Issue: Volume 15:Issue 7(2013:Jul.) Page Start: 613 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
23. Similar risk of exercise‐related hypoglycaemia for insulin degludec to that for insulin glargine in patients with type 1 diabetes: a randomized cross‐over trial. Issue 2 (27th November 2015) Authors: Heise, T.; Bain, S. C.; Bracken, R. M.; Zijlstra, E.; Nosek, L.; Stender‐Petersen, K.; Rabøl, R.; Rowe, E.; Haahr, H. L. Journal: Diabetes, obesity & metabolism Issue: Volume 18:Issue 2(2016) Page Start: 196 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
24. Single‐dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes. Issue 3 (22nd December 2014) Authors: Shiramoto, M.; Eto, T.; Irie, S.; Fukuzaki, A.; Teichert, L.; Tillner, J.; Takahashi, Y.; Koyama, M.; Dahmen, R.; Heise, T.; Becker, R. H. A. Journal: Diabetes, obesity & metabolism Issue: Volume 17:Issue 3(2015:Mar.) Page Start: 254 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
25. Steady‐state pharmacokinetics and glucodynamics of the novel, long‐acting basal insulin LY2605541 dosed once‐daily in patients with type 2 diabetes mellitus. Issue 4 (31st October 2013) Authors: Sinha, V. P.; Howey, D. C.; Choi, S. L.; Mace, K. F.; Heise, T. Journal: Diabetes, obesity & metabolism Issue: Volume 16:Issue 4(2014:Apr.) Page Start: 344 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
26. The dipeptidyl peptidase‐4 inhibitor linagliptin lowers postprandial glucose and improves measures of β‐cell function in type 2 diabetes1. Issue 10 (9th June 2014) Authors: Heise, T.; Larbig, M.; Patel, S.; Seck, T.; Hehnke, U.; Woerle, H.‐J.; Dugi, K. Journal: Diabetes, obesity & metabolism Issue: Volume 16:Issue 10(2014:Oct.) Page Start: 1036 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
27. Variability of glucose‐lowering effect as a limiting factor in optimizing basal insulin therapy: a review. Issue 8 (24th March 2013) Authors: Vora, J.; Heise, T. Journal: Diabetes, obesity & metabolism Issue: Volume 15:Issue 8(2013:Aug.) Page Start: 701 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗